-
1 Comment
GNI Group Ltd is currently in a long term downtrend where the price is trading 9.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.8.
GNI Group Ltd's total revenue rose by 33.5% to $3B since the same quarter in the previous year.
Its net income has increased by 905.3% to $791M since the same quarter in the previous year.
Finally, its free cash flow fell by 644.2% to $-37M since the same quarter in the previous year.
Based on the above factors, GNI Group Ltd gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | F |
| CurrencyCode | EUR |
| ISIN | JP3386370005 |
| PE Ratio | None |
|---|---|
| Target Price | None |
| Market Cap | 1B |
| Beta | 1.31 |
| Dividend Yield | None |
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for the treatment of pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; and F351 which is in Phase III clinical trial for the treatment of chronic hepatitis B liver fibrosis. In addition, the company is involved in the development of ETUARY which is in Phase II clinical trial for the treatment of radiation-induced lung injury with or without immune-related pneumonitis; F573 which is in Phase II clinical trial for the treatment of acute liver failure and acute-on-chronic liver failure; F351 which is in Phase I clinical trial for the treatment of MASH-advanced liver fibrosis; and F230 which is in Phase I clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops CG001419 which is in Phase Ia clinical trial for the treatment of acute and chronic pain; CG001419 which is in Phase Ia clinical trial for the treatment of solid tumors; and CG009301 which is in Phase Ia clinical trial for the treatment of leukemia and MYC+ cancers. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3G6.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
